DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 7,371.225 B2 Oldfield Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 7,371.225 B2 Oldfield Et Al USOO7371225B2 (12) United States Patent (10) Patent No.: US 7,371.225 B2 Oldfield et al. (45) Date of Patent: May 13, 2008 (54) METHOD FOR CONVECTION ENHANCED 5,720,720 A * 2/1998 Laske et al. ................ 604,500 DELIVERY OF THERAPEUTIC AGENTS 5,882,626 A 3/1999 Epstein et al. 6,435,714 B1 8, 2002 Bruder (75) Inventors: Edward H. Oldfield, Philomont, VA 6,438,198 B1 8/2002 Kohler (US); Russel R. Lonser, Silver Spring, 6,442,229 B1 8, 2002 Koehler et al. MD (US); Kayhan Garmestani, FOREIGN PATENT DOCUMENTS Potomac, MD (US); Martin W. EP O 882 454 A3 12, 1998 Brechbiel, Annandale, VA (US) WO WO 93,06868 4f1993 (73) Assignee: The United States of America as OTHER PUBLICATIONS represented by the Secretary of the . Department of Health and Human Laske et al. 1997, Tumor regression with regional distribution of the targeted toxin TF-CRM100 in patients with malignant brain tumors. Services, Washington, DC (US) Nature Medicine 3(12): 1362-1368.* - r Kobayashi et al. Jul. 1, 2001; Dynamic micro-magnetic resonance (*) Notice: Subject to any disclaimer, the term of this imaging of liver micro-metastasis in mice with a novel liver patent is extended or adjusted under 35 macromolecular magnetic resonance contrast agent DAB-AM64 U.S.C. 154(b) by 257 days. (1B4M-Gd)64. Cancer Research 61: 4966-4970.* Krollet al. 1996; Increasing volume of distribution to the brain with (21) Appl. No.: 10/528,310 interstitial infusion: Dose, rather than convection, might be the most important factor. Neurosurgery 38(4): 746-752.* (22) PCT Filed: Sep. 24, 2003 Lonser et al. 1998; Direct convective delivery of macromolecules to the spinal cord. J. Neurosurgery 89: 616-622.* (86). PCT No.: PCT/USO3/30.155 Wisneski et al. 1985; Absence of myocardial biochemical toxicity with a non ioninc contrast agentiopamidol. American Heart Journal S 371 (c)(1), Wosilait110 A. re,et al. 1981; only Competition the E. between being EE,serum albumin and (2), (4) Date: Mar. 17, 2005 soluble fraction of liver for binding of warfarin and other drugs. Res (87) PCT Pub. No.: WO2004/031348 M". inst Pharamcol. 32(1): 113-122; only the Bobo et al., Proc. Natl. Acad. Sci. USA 91:2076-2080, 1994. PCT Pub. Date: Apr. 15, 2004 Chen et al., J. Neurosurg 90:315-320, 1999. Debinski, Cancer Invest 2005-6):801-809, 2002 (Abstract). (65) Prior Publication Data US 2006/OO73101 A1 Apr. 6, 2006 (Continued) Primary Examiner Karen Cochrane Carlson Related U.S. Application Data (74) Attorney, Agent, or Firm—Klarduist Sparkman, LLP (60) gyal application No. 60/413,673, filed on Sep. (57) ABSTRACT A method for monitoring and controlling convection (51) Estoo (2006.01) enhanced delivery of a therapeutic agent to a target tissue is disclosed. A tracer that is detectable, for example, by mag (52) U.S. Cl. ...................................... ... 604/49 netic resonance imaging (MRI) and/or by X-ray computed (58) Field of Classification Search .................. 604/49; tomography (CT) is co-infused with the therapeutic agent A61 M 3 I/OO and used to monitor the distribution of the therapeutic agent See application file for complete search history. as it moves through the target tissue. The images obtained (56) References Cited during delivery are used to confirm delivery of the thera peutic agent to the target tissue and to avoid exposure of U.S. PATENT DOCUMENTS tissue outside of the targeted area to the therapeutic agent. In addition, the signal intensity of the images may be used to 4,339.426 A 7, 1982 Meares et al. 5,093,042 A 3, 1992 Counsell et al. confirm that the therapeutic agent has been delivered to the 5,415,867 A 5/1995 Minchey et al. target tissue at a desired concentration. 5,514,379 A * 5, 1996 Weissleder et al. ......... 424/426 5,660,814 A * 8/1997 Uggeri et al. .............. 424,936 29 Claims, 14 Drawing Sheets US 7,371.225 B2 Page 2 OTHER PUBLICATIONS Dendrimer Core With Reference to Their Pharmacokinetic Proper ties.” Magnetic Resonance in Medicine 45:454-460, 2001. Guridi et al., J. Neurosurg. 93:364-366, 2000. Kobayashi et al., “Dynamic Micro-Magnetic Resonance Imaging of Hall, Neurosurgery 46(3):544-551, 2000 (Abstract). Liver Micrometastasis in Mice with a Novel Liver Macromolecular Hamilton et al., Experimental Neurology 168: 155-161, 2001. Magnetic Resonance Contrast Agent DAB-Amó4-(1B4M-Gd).” Kobayashi et al., “Monoclonal antibody-dendrimer conjugates Cancer Research 61:4966-4970, 2001. enable radiolabeling of antibody with markedly high specific activ Kobayashi et al., “Novel Intravascular Macromolecular MRI Con ity with minimal loss of immunoreactivity,” http://link. Springer-ny. trast Agent With Generation-4 Polyamidoamine Dendrimer Core: com/link? service/journals/00259/contents/00/00293/ Accelerated Renal Excretion With Coinjection of Lysine.” Magnetic s002590000293ch002.htm, downloaded Jun. 22, 2001 (Abstract). Resonance in Medicine 46:457-464, 2001. Laske et al., J. Neurosurg 80:520-526, 1994. Kobayashi et al., “Novel Liver Macromolecular MR Contrast Agent Laske et al., J. Neurosurg 87:586-594, 1997. With a Polypropylenimine Diaminobutyl Dendrimer Core: Com Laske et al., Nature Medicine 3(12): 1362-1368, 1997. parison to the Vascular MR Contrast Agent With the Lieberman et al., J. Neurosurg, 82:1021-1029, 1995. Polyamidoamine Dendrimer Core.” Magentic Resonance in Medi Lieberman et al., J. Neurosurg. 92:928-934, 1999. cine 46:795-802, 2001. Lonser et al., J. Neurosurg. 89:610-615, 1998. Kobyashi et al., “Renal tubular damage detected by dynamic Lonser et al., J. Neurosurg. 89:616-622, 1998. micro-MRI with a dendrimer-based magnetic resonance contrast Lonser et al., J. Neurosurg, 97(4):905-913, 2002 (Abstract). agent.” Kidney International 61(6): 1980-1985, 2002. Maki et al., Gang To Kagaku Ryoho. 13(4 Pt 2):1603-1610, 1986 Konda, et al., “Specific targeting of folate-dendrimer MRI contrast (Abstract). agents to the high affinity folate receptor expressed in ovarian tumor Morrison et al., Am. J. Physiol. 266 (Regulatory Integrative Comp. xenografts,” MAGMA 12:104-113. 2001. Physiol. 35):R292-R305, 1994. Lam et al., “Analysis of In Vivo Imaging and Distribution of Morrison et al., Am. J. Physiol. 277 (Regulatory Integrative Comp. Macromolecules in CT and MRI via Convection Enhanced Deliv Physiol. 46):R1218-R1229, 1999. ery,” presented in a non-public forum to employees of the National Nguyen et al., J. Neurosurg, 98(3):584-590, 2003 (Abstract). Institutes of Health, Summer 1998. Oldfield et al., Curr: Top. Microbiol. Immunol. 234:97-114, 1998. Malik et al., “Dendrimer-platinate: a novel approach to cancer Ratliff et al., J. Neurosurg.95:1001-1011, 2001. chemotherapy,” Anti-Cancer Drugs 10:767-776, 1999. Wood et al., J. Neurosurg (Spine I), 90:115-120, 1999. Sato et al., “Pharmacokinetics and Enhancement Patterns of X-ray Transmission Imaging,” http://cfi.lbl.gov/-budinger/ Macromolecular MR Contrast Agent With Various Sizes of medTechdocs/Xray.html, downloaded Sep. 20, 2002. Polyamidoamine Dendrimer Cores.” Magnetic Resonance in Medi Zirzow et al., Neurochemical Research 24(2):301-305, 1999. cine 46:1169-1173, 2001. Caravan et al., “Gadolinium(III) Chelates as MRI Contrast Agents: Tajarobi et al., “Transport of poly amidoamine dendrimers across Structure, Dynamics, and Applications.” Chem. Rev., pp. 2293 Madin-Darby canine kidney cells.” International Journal of 2352, 1999. Pharmaceutics 215:263-267, 2001. Eichman et al., “Imaging of gold dendrimer nanocomposites in “Monitoring Infusion of Protein into Brain by Computed cells.” Mat. Res. Soc. Symp. Proc. 676:Y9.3.1-Y9.3.11, 2001. Tomography.” NIH Bioengineering Symposium, Feb. 1998. Kobayashi et al., “3D-Micro-MR Angiography of Mice Using Macromolecular MR Contrast Agents With Polyamidoamine * cited by examiner U.S. Patent May 13, 2008 Sheet 1 of 14 US 7,371.225 B2 FIG. U.S. Patent May 13, 2008 Sheet 2 of 14 US 7,371.225 B2 e U.S. Patent May 13 , 2008 Sheet 3 of 14 US 79 371.225 B2 U.S. Patent May 13, 2008 Sheet 4 of 14 US 7,371.225 B2 1200 1000 8OO 600 400 200 O 20 40 6O 80 100 120 140 Volume of infusion (microliters) FIG. 4 U.S. Patent May 13, 2008 Sheet 5 of 14 US 7,371.225 B2 20 18 16 14 1 2 O 20 40 60 80 100 120 Volume of infusion (microliters) FGS U.S. Patent May 13, 2008 Sheet 6 of 14 US 7,371.225 B2 FIG. 6 U.S. Patent May 13, 2008 Sheet 7 of 14 US 7,371.225 B2 300 250 E E 2OO 150 V 100 50 O O 2 4, 6 8 10 12 14 16 Distance (millimeters) FG. 7 U.S. Patent May 13, 2008 Sheet 8 of 14 US 7,371.225 B2 1600 1400 () S. 1200 9 5o 1OOO 9 S2 800 s 600 O C 400 E DO 200 O O 1 2 Post-infusion day FG. 8 U.S. Patent May 13, 2008 Sheet 9 of 14 US 7,371.225 B2 F.G. 9 U.S. Patent May 13, 2008 Sheet 10 of 14 US 7,371.225 B2 F.G. 10 U.S. Patent May 13, 2008 Sheet 11 of 14 US 7,371.225 B2 F.G. 11 U.S. Patent May 13, 2008 Sheet 12 of 14 US 7,371.225 B2 F.G. 12 U.S. Patent May 13, 2008 Sheet 13 of 14 US 7,371.225 B2 U.S. Patent May 13, 2008 Sheet 14 of 14 US 7,371.225 B2 2 1 OO O 9 BOO FOO O SOC AO) 3OO 2OO O O 5 2O 25 3O 35 AO 45 SO 55 30 35 lodins (mg/ml) FIG.
Load more

Recommended publications
  • Wo 2009/081169 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date PCT 2 July 2009 (02.07.2009) WO 2009/081169 A2 (51) International Patent Classification: KJELLSON, Fred [SE/SE]; IoPharma Technologies AB, A61K 49/04 (2006.01) Ideon Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE). KLAVENESS, J o [NO/SE]; IoPharma Technologies (21) International Application Number: AB, Ideon Science Park, Ole Romers Vag 12, SE-223 70 PCT/GB2008/004268 Lund (SE). (22) International Filing Date: (74) Agent: KIDD, Sara; Frank B. Dehn 6 Co., St. Bride's 22 December 2008 (22.12.2008) House, 10 Salisbury Square, London EC4Y 8ID (GB). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (30) Priority Data: EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, 0725070.7 21 December 2007 (21.12.2007) GB IL, IN, IS, IP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicant (for all designated States except US): IO- LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, PHARMA TECHNOLOGIES AB [SE/SE]; Ideon MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE).
    [Show full text]
  • Pharmacy Reengineering (PRE) V.0.5 Pre-Release Implementation
    PHARMACY REENGINEERING (PRE) Version 0.5 Pre-Release Implementation Guide PSS*1*129 & PSS*1*147 February 2010 Department of Veterans Affairs Office of Enterprise Development Revision History Date Revised Patch Description Pages Number 02/2010 All PSS*1*147 Added Revision History page. Updated patch references to include PSS*1*147. Described files, fields, options and routines added/modified as part of this patch. Added Chapter 5, Additive Frequency for IV Additives, to describe the steps needed to ensure correct data is in the new IV Additive REDACTED 01/2009 All PSS*1*129 Original version REDACTED February 2010 Pharmacy Reengineering (PRE) V. 0.5 Pre-Release i Implementation Guide PSS*1*129 & PSS*1*147 Revision History (This page included for two-sided copying.) ii Pharmacy Reengineering (PRE) V. 0.5 Pre-Release February 2010 Implementation Guide PSS*1*129 & PSS*1*147 Table of Contents Introduction ................................................................................................................................. 1 Purpose ....................................................................................................................................1 Project Description ....................................................................................................................1 Scope ........................................................................................................................................3 Menu Changes ..........................................................................................................................4
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Pharmacologyonline 2: 727-753 (2010) Ewsletter Bradu and Rossini
    Pharmacologyonline 2: 727-753 (2010) ewsletter Bradu and Rossini COTRAST AGETS - IODIATED PRODUCTS. SECOD WHO-ITA / ITA-OMS 2010 COTRIBUTIO O AGGREGATE WHO SYSTEM-ORGA CLASS DISORDERS AD/OR CLUSTERIG BASED O REPORTED ADVERSE REACTIOS/EVETS Dan Bradu and Luigi Rossini* Servizio Nazionale Collaborativo WHO-ITA / ITA-OMS, Università Politecnica delle Marche e Progetto di Farmacotossicovigilanza, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary From the 2010 total basic adverse reactions and events collected as ADRs preferred names in the WHO-Uppsala Drug Monitoring Programme, subdivided in its first two twenty years periods as for the first seven iodinated products diagnostic contrast agents amidotrizoate, iodamide, iotalamate, iodoxamate, ioxaglate, iohexsol and iopamidol, their 30 WHO-system organ class disorders (SOCDs) aggregates had been compared. Their common maximum 97% levels identified six SOCDs only, apt to evaluate the most frequent single ADRs for each class, and their percentual normalization profiles for each product. The WILKS's chi square statistics for the related contingency tables, and Gabriel’s STP procedure applied to the extracted double data sets then produced profile binary clustering, as well as Euclidean confirmatory plots. They finally showed similar objectively evaluated autoclassificative trends of these products, which do not completely correspond to their actual ATC V08A A, B and C subdivision: while amidotrizoate and iotalamate, and respectively iohesol and iopamidol are confirmed to belong to the A and B subgroups, ioxaglate behaves fluctuating within A, B and C, but iodamide looks surprizingly, constantly positioned together with iodoxamate as binary/ternary C associated. In view of the recent work of Campillos et al (Science, 2008) which throws light on the subject, the above discrepancies do not appear anymore unexpected or alarming.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Pharmacy and Poisons Act 1979
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS ACT 1979 1979 : 26 TABLE OF CONTENTS PART I PRELIMINARY 1 Short title 2 Interpretation PART II THE PHARMACY COUNCIL 3 The Pharmacy Council 4 Membership of the Council 4A Functions of the Council 4B Protection from personal liability 4C Annual Report 5 Proceedings of the Council, etc PART III REGISTRATION OF PHARMACISTS 6 Offence to practise pharmacy if not registered 7 Registration as a pharmacist 7A Re-registration as non-practising member 7AA Period of validity of registration 8 Code of Conduct 9 Pharmacy Profession Complaints Committee 10 Investigation of complaint by Committee 10A Inquiry into complaint by Council 10B Inquiry by Council of its own initiative 11 Surrender of registration 12 Restoration of name to register 1 PHARMACY AND POISONS ACT 1979 13 Proof of registration 14 Appeals 14A Fees 14B Amendment of Seventh Schedule 15 Regulations for this part PART IV REGISTRATION OF PHARMACIES 16 Register of pharmacies 17 Registration of premises as registered pharmacies 18 Unfit premises: new applications 19 Unfit premises: registered pharmacies 20 Appeals 21 When certificates of unfitness take effect 22 Regulations for this Part PART V CONTROL OF PRESCRIPTIONS AND IMPORTATION 23 Prescriptions to be in a certain form 23A Validity of a prescription 24 Supply by registered pharmacist of equivalent medicines 25 Restrictions on the importation of medicines 26 Declaration relating to imported medicines [repealed] PART VI CONTROL OF DRUGS 27 Certain substances to be sold on prescription
    [Show full text]
  • Ep 0119020 A2
    European Patent Office © Publication number: 0 119 020 Office europeen des brevets A2 © EUROPEAN PATENT APPLICATION © Application number: 84300949.9 © Int. CI.3: A 61 K 9/50 © Date of filing: 14.02.84 © © Priority: 15.02.83 GB 8304165 Inventor: Ridgway, Frank 03.10.83 GB 8326448 Bellefield Noctorum Lane 06 01 84 GB 8400306 Noctorum Birkenhead Merseyside(GB) © Inventor: Payne, Nicholas 1. ©Date of publication of application: SAntoiw Road P«^r 19.09.84 Bulletin 84138 W.rral Merseyside(GB) © Inventor: © Designated Contracting States: Timmins, Peter AT BE CH DE FR GB FT LI LU NL SE 34ThornleyRoadMoreton Wirral Merseyside(GB) © Applicant: E.R. Squibb & Sons, Inc. c\ , _ „t Uwrenceville-Princeton Road ® '"v.f nt°I: Groom/ Ch?f Vanessa Princeton. N.J. 08540{US) 1 West Cottages Leadpipe Lane Cotherstone Barnard Castle County Durham(GB) © Representative: Thomas, Roger Tamlyn et al, D. Young & Co. 10 Staple Inn London WC1V7RD(GB) (54) Method of preparing liposomes and products produced thereby. ©A A method is provided for preparing a stable liposome precursors in the form of a particulate carrier materials coated with thin films of liposome components, which method includes the steps of dissolving at least one liposome-forming amphipathic lipid, optionally, at least one biologically active compound, and, optionally, at least one adjuvant in a suitable solvent and employing the resulting solution to coat a suitable particulate carrier material which is substantially insoluble in the above-mentioned solvent, to form thin films of liposome components thereon. Upon exposing the coated carrier material to water, the thin films of liposome components hydrate.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • US 2007/0259031 A1 Bankiewicz Et Al
    US 20070259031A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0259031 A1 Bankiewicz et al. (43) Pub. Date: Nov. 8, 2007 (54) COMPOSITIONS AND METHODS FOR (22) Filed: Apr. 26, 2007 CONVECTION ENHANCED DELVERY OF HIGH MOLECULAR WEIGHT Related U.S. Application Data NEUROTHERAPEUTICS (60) Provisional application No. 60/795,371, filed on Apr. (75) Inventors: Krystof S. Bankiewicz, Oakland, CA 26, 2006. Provisional application No. 60/900,492, (US); Sandeep Kunwar, Hillsborough, filed on Feb. 9, 2007. CA (US) Publication Classification Correspondence Address: JOHN P. O'BANION (51) Int. C. OBANON & RITCHEY LLP A6II 38/17 (2006.01) 4OO CAPTOL MALL SUTE 15SO A 6LX 9/27 (2006.01) SACRAMENTO, CA 95814 (US) (52) U.S. Cl. ............................... 424/450; 514/2; 977/907 (73) Assignee: THE REGENTS OF THE UNIVER SITY OF CALIFORNIA, Oakland, CA (57) ABSTRACT (US) A method of therapeutic treatment of CNS disorders using (21) Appl. No.: 11/740,508 local convection enhanced delivery. Patent Application Publication Nov. 8, 2007 Sheet 1 of 18 US 2007/0259031A1 : FIG. 1 Patent Application Publication Nov. 8, 2007 Sheet 2 of 18 US 2007/0259031A1 Tota Tuimor Mass: 1.1 cm3 Ls-Gd-CPT-11 (Vd): 0.134 cm3 Tumor MaSS Covered. 12.2% FIG 2 Patent Application Publication Nov. 8, 2007 Sheet 3 of 18 US 2007/0259031A1 Liposones FIG 3 Patent Application Publication Nov. 8, 2007 Sheet 4 of 18 US 2007/0259031A1 FIG. 4 Patent Application Publication Nov. 8, 2007 Sheet 5 of 18 US 2007/0259031A1 Cat ifisic m -is ...rt YYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYu .S.
    [Show full text]
  • 3258 N:O 1179
    3258 N:o 1179 LIITE 1 BILAGA 1 LÄÄKELUETTELON AINEET ÄMNENA I LÄKEMEDELSFÖRTECKNINGEN Latinankielinen nimi Suomenkielinen nimi Ruotsinkielinen nimi Englanninkielinen nimi Latinskt namn Finskt namn Svenskt namn Engelskt namn Abacavirum Abakaviiri Abakavir Abacavir Abciximabum Absiksimabi Absiximab Abciximab Acamprosatum Akamprosaatti Acamprosat Acamprosate Acarbosum Akarboosi Akarbos Acarbose Acebutololum Asebutololi Acebutolol Acebutolol Aceclofenacum Aseklofenaakki Aceklofenak Aceclofenac Acediasulfonum natricum Asediasulfoninatrium Acediasulfonnatrium Acediasulfone sodium Acepromazinum Asepromatsiini Acepromazin Acepromazine Acetarsolum Asetarsoli Acetarsol Acetarsol Acetazolamidum Asetatsoliamidi Acetazolamid Acetazolamide Acetohexamidum Asetoheksamidi Acetohexamid Acetohexamide Acetophenazinum Asetofenatsiini Acetofenazin Acetophenazine Acetphenolisatinum Asetofenoli-isatiini Acetfenolisatin Acetphenolisatin Acetylcholini chloridum Asetyylikoliinikloridi Acetylkolinklorid Acetylcholine chloride Acetylcholinum Asetyylikoliini Acetylkolin Acetylcholini Acetylcysteinum Asetyylikysteiini Acetylcystein Acetylcysteine Acetyldigitoxinum Asetyylidigitoksiini Acetyldigitoxin Acetyldigitoxin Acetyldigoxinum Asetyylidigoksiini Acetyldigoxin Acetyldigoxin Acetylisovaleryltylosini Asetyyli-isovaleryyli- Acetylisovaleryl- Acetylisovaleryltylosine tartras tylosiinitartraatti tylosintartrat tartrate Aciclovirum Asikloviiri Aciklovir Aciclovir Acidum acetylsalicylicum Asetyylisalisyylihappo Acetylsalicylsyra Acetylsalicylic acid Acidum alendronicum
    [Show full text]
  • Gadoversetamide (BAN, USAN, Rinn) Is Excreted in the Urine Within 24 Hours
    1480 Contrast Media gadolinium-containing contrast media should be restricted in pa- Gadoteric Acid (BAN, rINN) Adverse Effects and Precautions tients with severe renal impairment (GFR less than Acide Gadotérique; Ácido gadotérico; Acidum Gadotericum; As for Gadopentetic Acid, above. 30 mL/minute per 1.73 m2). The MHRA contra-indicates the use Gadoteerihappo; Gadotersyra; Gd-DOTA; ZK-112004. Hydro- ◊ Reviews. of gadodiamide or gadopentetate in such patients (other gadolin- ium-containing contrast media are under review), whereas the gen [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraaceto(4−)]- 1. Runge VM, Parker JR. Worldwide clinical safety assessment of gadoteridol injection: an update. Eur Radiol 1997; 7 (suppl 5): FDA advises that all gadolinium-containing contrast media gadolinate(1−); Hydrogen [1,4,7,10-tetrakis(carboxylatomethyl)- 4 243–5. should be avoided unless the diagnostic information is essential 1,4,7,10-tetra-azacyclododecane-κ N]gadolinate(1−). and cannot be obtained another way. The FDA gives a similar Гадотеровая Кислота Hypersensitivity. For a report of an anaphylactoid reaction with gadoteridol, see under Adverse Effects of Gadopentetic Ac- warning for use in patients with acute renal failure associated C16H25GdN4O8 = 558.6. with hepato-renal syndrome or around the time of liver trans- CAS — 72573-82-1. id, p.1479. plantation. The value of haemodialysis to remove gadolinium- ATC — V08CA02. Pharmacokinetics containing contrast media after use is unknown. ATC Vet — QV08CA02. Gadoteridol is distributed into extracellular fluid after intrave- 1. Perazella MA, Rodby RA. Gadolinium-induced nephrogenic nous injection. About 94% of a dose is excreted unchanged in the systemic fibrosis in patients with kidney disease.
    [Show full text]